Semaglutide for Alcohol Use Disorder: What the ...

The VA trial testing semaglutide for alcohol use disorder could reshape understanding of GLP-1 drugs. This article examines the research, misconceptions

Semaglutide Microdosing: Low-Dose GLP-1 Research

Semaglutide microdosing explores low GLP-1 doses for weight loss, aiming to reduce misuse risks. Research is nascent, with no consensus on efficacy or

AOD-9604 and Tirzepatide Stack: Metabolic Syner...

AOD-9604 and tirzepatide are being studied for their potential metabolic synergy in targeting stubborn fat. This article examines the research, regulatory

Semaglutide vs. Retatrutide: FDA Panel’s Triple...

The FDA peptide panel is evaluating retatrutide, a triple-agonist, against semaglutide for weight loss. Research shows retatrutide may achieve greater

Semaglutide Safety After Compounding Pharmacy C...

MedPage Today's investigation into compounded semaglutide revealed dosing errors and contamination risks. This article examines the research on

AOD-9604 and CJC-1295 Stack: Research on Body R...

Research examines AOD-9604 and CJC-1295 for body recomposition during semaglutide use. Current data on mitigating muscle loss remain limited and